DOW JONES27,960.80-1031.61 -3.56%
S&P 5003,225.89-111.86 -3.35%
NASDAQ9,221.28-355.31 -3.71%

Morgan Stanley Upgrades Acceleron Pharma to Overweight, Raises Price Target to $122

Morgan Stanley analyst Jeffrey Hung upgrades Acceleron Pharma (NASDAQ:XLRN) from Equal-Weight to Overweight and raises the price target from $52 to $122.

Benzinga · 02/03/2020 10:53

Morgan Stanley analyst Jeffrey Hung upgrades Acceleron Pharma (NASDAQ:XLRN) from Equal-Weight to Overweight and raises the price target from $52 to $122.